Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients.
BACKGROUND
Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India.


OBJECTIVE
To compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressive disorder.


METHODS
In this prospective study, patients (n=60) were randomly assigned to treatment with moclobemide or imipramine for 6 weeks. Efficacy of the drugs was assessed by observing the mean change in scores on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Scale (MADRS).


RESULTS
Both the groups showed significant decrease in scores at the end of 6 weeks. Patients who received moclobemide had a better side-effect profile.


CONCLUSIONS
Moclobemide is an effective antidepressant and is better tolerated than imipramine.
Avasthi
Ajit
A
Additional Professor of Psychiatry, Postgraduate Institute of Medical Education and Research.
Kulhara
Parmanand
P
Singh
Gagandeep
G
Sharma
Rajni
R
Kaur
Rajinder P
RP